Pancreatic ductal adenocarcinoma (PDA) remains a lethal malignancy despite much progress concerning its molecular characterization. PDA tumours harbour four signature somatic mutations [1] [2] [3] [4] in addition to numerous lower frequency genetic events of uncertain significance 5 . Here we use Sleeping Beauty (SB) transposonmediated insertional mutagenesis 6,7 in a mouse model of pancreatic ductal preneoplasia 8 to identify genes that cooperate with oncogenic Kras G12D to accelerate tumorigenesis and promote progression. Our screen revealed new candidate genes for PDA and confirmed the importance of many genes and pathways previously implicated in human PDA. The most commonly mutated gene was the X-linked deubiquitinase Usp9x, which was inactivated in over 50% of the tumours. Although previous work had attributed a pro-survival role to USP9X in human neoplasia 9 , we found instead that loss of Usp9x enhances transformation and protects pancreatic cancer cells from anoikis. Clinically, low USP9X protein and messenger RNA expression in PDA correlates with poor survival after surgery, and USP9X levels are inversely associated with metastatic burden in advanced disease. Furthermore, chromatin modulation with trichostatin A or 5-aza-29-deoxycytidine elevates USP9X expression in human PDA cell lines, indicating a clinical approach for certain patients. The conditional deletion of Usp9x cooperated with Kras G12D to accelerate pancreatic tumorigenesis in mice, validating their genetic interaction. We propose that USP9X is a major tumour suppressor gene with prognostic and therapeutic relevance in PDA.
Pancreatic ductal adenocarcinoma (PDA) remains a lethal malignancy despite much progress concerning its molecular characterization. PDA tumours harbour four signature somatic mutations [1] [2] [3] [4] in addition to numerous lower frequency genetic events of uncertain significance 5 . Here we use Sleeping Beauty (SB) transposonmediated insertional mutagenesis 6, 7 in a mouse model of pancreatic ductal preneoplasia 8 to identify genes that cooperate with oncogenic Kras G12D to accelerate tumorigenesis and promote progression. Our screen revealed new candidate genes for PDA and confirmed the importance of many genes and pathways previously implicated in human PDA. The most commonly mutated gene was the X-linked deubiquitinase Usp9x, which was inactivated in over 50% of the tumours. Although previous work had attributed a pro-survival role to USP9X in human neoplasia 9 , we found instead that loss of Usp9x enhances transformation and protects pancreatic cancer cells from anoikis. Clinically, low USP9X protein and messenger RNA expression in PDA correlates with poor survival after surgery, and USP9X levels are inversely associated with metastatic burden in advanced disease. Furthermore, chromatin modulation with trichostatin A or 5-aza-29-deoxycytidine elevates USP9X expression in human PDA cell lines, indicating a clinical approach for certain patients. The conditional deletion of Usp9x cooperated with Kras G12D to accelerate pancreatic tumorigenesis in mice, validating their genetic interaction. We propose that USP9X is a major tumour suppressor gene with prognostic and therapeutic relevance in PDA.
The biological sequelae of PDA has been partially attributed to frequent and well characterized mutations in KRAS (.90%), CDKN2A (.90%), TP53 (70%) and SMAD4 (55%) [1] [2] [3] [4] . Recent genomewide analyses have uncovered numerous additional somatic genetic alterations, although the functional relevance of most remains uncertain 5 . To explore the molecular genesis of PDA we previously generated a mouse model of pancreatic intraepithelial neoplasia (mPanIN) by conditionally expressing an endogenous Kras G12D allele in the developing pancreas 8 . Mice with mPanIN spontaneously progress to mouse PDA (mPDA) after a long and variable latency, providing an opportunity to characterize genes that cooperate with Kras G12D to promote early mPDA. We hypothesized that such genes could be directly identified by applying insertional mutagenesis strategies 6, 7, 10, 11 in our mPanIN model, and that these candidates could represent 'drivers' of PDA development.
Accordingly, we interbred our mPanIN model with two distinct SB transposon systems and monitored mice for early disease progression. Our initial approach used the well characterized CAGGS-SB10 transgenic allele to promote transposition 6 . Although CAGGS-SB10 promoted PDA, a variety of non-pancreatic neoplasms and a paucity of identified common insertion sites (CIS) in the recovered pancreatic neoplasms precluded a comprehensive analysis, potentially reflecting the variegated expression of CAGGS-SB10 (ref. 12) (Supplementary  Figs 1a and 2, and Supplementary Tables 1 and 3b) .
To increase the specificity and potency of SB mutagenesis, we generated a conditional SB13 mutant mouse by targeting the Rosa26 locus in embryonic stem cells ( Supplementary Fig. 3a, b ). The pancreas-specific expression and function of the conditional SB13 allele was confirmed ( Supplementary Fig. 3c ), and we found that SB13-induced transposition by itself did not promote lethality or pancreatic tumorigenesis ( Fig. 1a and Supplementary Fig. 4a ). In contrast, Kras LSL-G12D ; Pdx1-cre; T2/Onc; Rosa26-LSL-SB13 mice rapidly progressed and succumbed to invasive pancreatic neoplasms ( Fig. 1a -c). A cohort of 117 Kras LSL-G12D ; Pdx1-cre; T2/Onc; Rosa26-LSL-SB13 mice ( Supplementary Fig. 1b ) was monitored for tumour development, and 103 of these mice were available for full necropsy and tissue procurement. The majority of such mice harboured multi-focal pancreatic tumours, and 198 distinct primary tumours and metastases were subjected to histological and molecular analysis. Most mice had invasive carcinomas (66 of 103) that consisted of classical mPDA (78.8%) or invasive cystic neoplasms (21.2%); 34.8% of mice also contained metastases predominantly in their liver and lungs ( Supplementary Fig. 4c ). The remainder of the mice (37 of 103) had pre-invasive pancreatic tumours consisting of high-grade
{Lists of participants and their affiliations appear at the end of the paper. 1 mPanIN and cyst-forming papillary neoplasms ( Supplementary  Fig. 4b ).
The candidate genes identified from the SB13 screen represented unanticipated candidates as well as many genes and pathways previously implicated in human PDA ( Table 1 and Supplementary Tables 2, 3a and 4). Indeed, various members of the TGF-b pathway, including Smad3, Smad4, Tgfbr1 and Tgfbr2, were collectively mutated in 32% of the tumours. Also, the Rb-p16Ink4a pathway was disrupted in 21% of the tumours. CISs representing the orthologues of additional human PDA genes included Fbxw7 (24.2%), Arid1a (19.1%), Acvr1b (19.1%), Stk11 (also called Lkb1) (6.5%), Mll3 (6%), Smarca4 (6%) and Pbrm1 (4.5%) 5, [13] [14] [15] . Trp53 was the only commonly mutated PDA gene conspicuously absent, although the p53 regulatory deubiquitinase Usp7 was a CIS (6.5%) 16 . Several CISs previously noted in insertional mutagenesis screens for hepatocellular carcinoma or gastrointestinal tract adenomas, but not typically mutated in PDA, were also identified in this study, including Zbtb20, Nfib and Ube2h in liver tumours 10 , and Pten, Tcf12, Ppp1r12a and Ankrd11 in gastrointestinal tract adenoma/ adenocarcinoma 11 . This indicates that many tumour progression pathways may be common to pancreatic, liver and gastrointestinal/ colorectal tumours.
Unexpectedly, the most frequent CIS observed was the X-linked deubiquitinase Usp9x, a gene that had not been previously associated with PDA or other types of carcinoma in humans or mouse models. Indeed, the COSMIC data base revealed only one USP9X mutation in a case of ovarian cancer, although the functional relevance of this mutation has not been characterized (COSMIC mutation ID 73237). Usp9x was disrupted in over 50% of all tumours, with 341 insertions noted in the 101 tumours harbouring this CIS ( Fig. 1d and Table 1 ). Furthermore, Usp9x was also identified as a CIS in four samples from the initial SB10 screen ( Supplementary Table 1 ), supporting its candidacy as a PDA genetic determinant. We confirmed that Usp9x was disrupted in tumours by isolating chimaeric fusion mRNAs that spliced the Usp9x transcript to the T2/Onc transposon (Fig. 1e ). In addition, the Usp9x protein was specifically absent in neoplastic cells in pancreatic tumours bearing intragenic insertions ( Fig. 1f, g) .
To characterize the cellular and molecular pathways affected by Usp9x in PDA, we used RNA interference to deplete Usp9x levels in 
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mPDA cell lines ( Supplementary Fig. 5a ). Although Usp9x depletion did not affect the proliferation of monolayer cultures ( Supplementary  Fig. 5b) , it significantly increased colony formation in soft agar ( Fig. 2a , Supplementary Fig. 5c ) compared to cells transfected with scrambled short hairpin RNAs. Furthermore, knock down of Usp9x potently suppressed anoikis in mPDA cells (Fig. 2b) . These properties of Usp9x were predominantly dependent on its intrinsic deubiquitinase activity ( Supplementary Fig. 6a, b ). Because USP9X was previously reported to positively regulate SMAD4 transcriptional activity 17 and SMAD4 is commonly mutated in PDA 4 , we hypothesized that Usp9x loss would attenuate Smad4 function or TGF-b responsiveness in PDA cell lines. However, irrespective of Usp9x expression level, mPDA cell lines expressed Smad4 and were equally sensitive to p21 induction, growth inhibition and morphological alterations after exposure to TGF-b1 ( Supplementary  Fig. 7 ). Therefore, we were unable to ascribe a specific role to Usp9x in the regulation of the Smad4-TGF-b pathway in mPDA cells or tumours.
We next investigated several additional proteins reported to be regulated by Usp9x and involved in pathways relevant to cellular transformation. Although USP9X has been shown to bind to and regulate two proteins involved in cell survival, ASK1 (ref. 18 ) and MCL1 (refs 9, 19), we could not detect obvious changes in Ask1 or Mcl1 protein levels upon Usp9x loss ( Fig. 2c ). Usp9x has also been reported to deubiquitinate and thereby stabilize the E3 ligase Itch 20 ; decreased protein levels of Itch were observed in mouse and human PDA cells upon the depletion of Usp9x ( Fig. 2c and Supplementary  Fig. 8a ). Notably, ectopic Itch expression was sufficient to promote anoikis in mPDA cells (Fig. 2d ), and Itch was partially responsible for the ability of Usp9x to promote anoikis and suppress colony formation ( Supplementary Fig. 6c, d ). Because Itch is known to promote the degradation of several proteins relevant to cell proliferation and survival 21 , we evaluated the protein expression of likely candidates including c-Jun, p63 and c-Flip but observed no alterations (Supplementary Fig. 8b ). Furthermore, the Itch gene was identified as a CIS in 13% of cases (Supplementary Table 2 ). Therefore, Usp9x mutation may promote tumorigenesis in part by disabling Itch function, and the Usp9x-Itch pathway may work to constrain pancreatic tumorigenesis.
To determine whether USP9X expression is aberrant in human PDA, three distinct patient cohorts were assessed. First, we analysed a cohort of 100 Australian patients who underwent surgery for localized PDA and had detailed information available concerning clinicalpathological characteristics and outcome ( Supplementary Fig. 9 and Supplementary Tables 5 and 6 ). Tumour DNA from 88 patients in this cohort failed to yield somatic mutations in USP9X, consistent with previous reports 5 (data not shown). Notably, the low expression of USP9X mRNA correlated with poor survival after surgery (P 5 0.0076) (Fig. 3a) , and multivariate analysis revealed that USP9X expression was an independent poor prognostic factor after surgery (Supplementary Table 7 ). We next analysed autopsy specimens from a separate cohort of 42 American patients to determine that USP9X protein expression inversely correlated with a widespread metastatic pattern (P 5 0.0212) (Fig. 3b) , and bore no relation to SMAD4 expression (Supplementary Table 8 ). A third collection of PDA specimens obtained from resected German patients (n 5 404) was used to determine that USP9X and ITCH protein levels were decreased ( Supplementary Fig. 10 ) and expressed in a similar manner (Spearman-Rho correlation 5 0.47; P , 0.01; Supplementary Table 9a ) in tumours compared to normal pancreatic tissue. Furthermore, the proportion of tumours that had undetectable USP9X (13.6%) or ITCH (30.5%) protein correlated with a worse outcome ( Supplementary Fig. 11 , Supplementary Table 9b , c), particularly regarding USP9X in the subset of high-grade tumours ( Fig. 3c and Supplementary Tables 10 and 11 ). Collectively, these findings implicate the loss of USP9X expression as a relevant event in human pancreatic cancer progression.
We found that USP9X was expressed throughout murine and human tumour development and lost focally in PDAs (Supplementary Figs 12 and 13 ). Additionally, human PDA cell lines expressed lower levels of USP9X compared to non-PDA cancer cell lines ( Supplementary Fig. 14) . To investigate additional potential mechanisms of USP9X regulation in PDA, human cell lines were treated with the DNA methylase inhibitor 5-aza-29-deoxycytidine and the HDAC inhibitor trichostatin A. Both inhibitors modestly increased the USP9X mRNA and protein levels in most cell lines, indicating that USP9X may be epigenetically silenced in vivo ( Fig. 3d and Supplementary Fig. 15 ). Furthermore, although the promoter region of USP9X was not heavily methylated in tumour samples or PDA cells harbouring low protein expression (data not shown), treatment with 5-aza-29deoxycytidine did decrease colony formation of human PDA cells and this was partially reversed by concomitantly knocking down USP9X ( Supplementary Fig. 16 ).
To confirm that Kras G12D cooperated with Usp9x loss to promote pancreatic cancer, a conditional Usp9x fl allele was generated (Supplementary Fig. 17a ) and interbred with Kras LSL-G12D ; Pdx1-cre mice to evaluate the impact on mPanIN progression. The mosaic expression of Usp9x in pancreas from Pdx1-cre; Usp9x fl/y mice was confirmed by immunohistochemistry ( Supplementary Fig. 17b ). We found that all hemizygous male mice and heterozygous female mice carriers of the Usp9x fl allele in the background of Kras LSL-G12D ; Pdx1-cre rapidly developed advanced mPanIN and microinvasive neoplasms within 3 months of age (Fig. 3e, f and Supplementary Fig. 18 ). Immunohistochemical analysis of mPanINs from heterozygous female mice demonstrated absence of Usp9x expression in the pre-neoplastic and neoplastic cells ( Supplementary Fig. 18 ), indicative of additional events such as X inactivation of the other locus in female mice 22, 23 . mPanINs in Kras LSL-G12D ; Pdx1-cre; Usp9x fl mice expressed intranuclear Smad4, similar to Kras LSL-G12D ; Pdx1-cre mice (Supplementary Fig. 19a ). Additionally, early passage pancreatic cell cultures 
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prepared from these mice confirmed the absence of the Usp9x protein and altered regulation of Itch ( Supplementary Fig. 19b ). Although some mice died of local or metastatic pancreatic cancer, aggressive oral papillomas often required the culling of young mice and demonstrated that Kras G12D and Usp9x loss also cooperated to transform keratinocytes ( Supplementary Fig. 19c ). Although a recent report implicated USP9X as a pro-survival gene by stabilizing MCL1 (ref. 9) , potential inhibitors of USP9X should be developed with caution as we find that Usp9x has tissue-specific effects including a tumour suppressor role in oncogenic Kras-initiated pancreatic carcinoma. USP9X is probably epigenetically silenced in a subset of PDA, thus explaining why previous DNA sequencing efforts have failed to identify this as a participant in carcinogenesis, and indicating that clinically available epigenome modulators may be beneficial agents in such patients. ITCH is a likely mediator of pancreatic tumour suppression by USP9X, and continued investigation of the USP9X-ITCH pathway is warranted. More generally, the identification of Usp9x through the use of transposon mutagenesis reaffirms the utility of in vivo mouse cancer screens to complement the direct investigation of human cancer. Rosa26-LSL-SB13 strains were interbred to generate Kras LSL-G12D ; Pdx1-cre, Kras LSL-G12D ; Pdx1-cre; T2/Onc; CAGGS-SB10 and Kras LSL-G12D ; Pdx-1-cre; T2/ Onc; Rosa26-LSL-SB13 compound mutant mice. Non-quadruple mutant mice represented the comparison cohorts. Kras LSL-G12D and Pdx1-cre mice were interbred with Usp9x fl mice to generate the Kras LSL-G12D ; Pdx1-cre; Usp9x fl/1 and Kras LSL-G12D ; Pdx1-cre; Usp9x fl/y compound mutant mice, as well as the two control cohorts Pdx1-cre; Usp9x fl/y and Kras LSL-G12D ; Pdx1-cre. Usp9x fl mice were generated by Ozgene Pty. Ltd. Mice were maintained in compliance with the UK home office regulations. Splinkerette PCRs were performed as described previously 25, 26 . Reads from sequenced tumours were mapped to the mouse genome assembly NCBI m37 and merged together to identify SB insertion sites, as previously described 25 . Redundant sequences, as well as insertions in the En2 gene and in the T2/Onc donor concatemer resident chromosome (chromosome 1), were removed. Mouse survival curves and cell culture experiments were analysed with the GraphPad prism program. The IHC histoscoring from the TMA samples and Kaplan-Meier survival curves were analysed with SPSS18, and the Spearman-Rho correlation coefficient (two-sided) between USP9X and ITCH was calculated. The IHC USP9X histoscore and analysis was conducted using Fisher's exact test on post-mortem samples. 6) and Rosa26-LSL-SB13 strains were interbred to generate Kras LSL-G12D ; Pdx1-cre; T2/Onc; CAGGS-SB10 (KCTSB10) and Kras LSL-G12D ; Pdx-1-cre; T2/Onc; Rosa26-LSL-SB13 (KCTSB13) compound mutant mice. Non-quadruple mutant mice represented the comparison cohorts. Genomic DNA from tumours developed in KCTSB10 and KCTSB13 mice was obtained using the Puregene Core Kit A (Qiagen) and splinkerette PCRs were performed as described previously 25, 26 . For the KCU cohort, Kras LSL-G12D and Pdx1-cre mice were interbred with Usp9x fl mice to generate the Kras LSL-G12D ; Pdx1-cre; Usp9x fl/1 and Kras LSL-G12D ; Pdx1-cre; Usp9x fl/y (KCU) compound mutant mice, as well as the two control cohorts Pdx1-cre; Usp9x fl/y (CU) and Kras LSL-G12D ; Pdx1cre (KC). Generation of Rosa26-LSL-SB13 knock-in mice. TL1 ES cells 27 were electroporated with linearized pRosa26-LSL-SA-SB13-BGHpolyA targeting construct and correctly targeted puromycin-resistant clones were identified by Southern blot. Two positives clones exhibiting a normal karyotype were used to generate chimaeric mice by microinjection into C57BL/6 blastocysts. Germline transmission of the targeted allele was confirmed by Southern blot analysis of tail DNA from the agouti offspring. T2/Onc excision PCR. Genomic DNAs were obtained from Pdx1-cre; T2/Onc; Rosa26-LSL-SB13 and T2/Onc; Rosa26-LSL-SB13 mice and primers used to assess the excision of the T2/Onc concatemer in the Pdx1-cre; T2/Onc; Rosa26-LSL-SB13 mice were 59-TGTGCTGCAAGGCGATTA-39 and 59-ACCATGATTACGCC AAGC-39. CIS analysis. For the statistical analysis, redundant sequences, as well as insertions in the En2 gene and in the T2/Onc donor concatemer resident chromosome (chromosome 1), were removed and 90,007 non-redundant insertion sites ( Supplementary Table 3 ) were used to identify CISs using a Gaussian kernel convolution framework (GKC) 28 . Reads from sequenced tumours were mapped to the mouse genome assembly NCBI m37 and merged together to identify SB insertion sites, as previously described 25 . An enhanced version of the framework was developed for SB screens to account for the local density of TA sites within the genome 25 . For example, a genomic region containing a large number of insertion sites but a low density of TA sites is considered to be significant and thereby identified as a candidate CIS. Conversely, a region with a large number of insertion sites but also containing a high density of TA sites is determined to be less significant, as the transposons have more 'target' sites into which they can integrate. Multiple kernel scales were used in the GKC framework (widths of 15K, 30K, 50K, 75K, 120K and 240K nucleotides). CISs predicted across multiple scales and overlapping in their genomic locations were clustered together, such that the CIS with the smallest genomic 'footprint' was reported as the representative CIS. For highly significant CISs with narrow spatial distributions of insertion sites, the 15K kernel is typically the scale on which CISs are identified. Additional statistical analysis of insertion sites was performed using a Monte Carlo framework 10 . CISs were compared to previously published data sets of human pancreatic cancer genetics 5, 29, 30 . Detection of Usp9x-T2/Onc fusion mRNA by RT-PCR in SB tumours. Total RNA was extracted from snap-frozen SB tumours using the RNeasy Mini kit (Qiagen), and total RNA (1 mg) was reverse transcribed into cDNA using the High Capacity RNA-to-cDNA kit (Applied Biosystems). RT-PCR was carried out with a nested PCR approach using primers of mouse Usp9x exon 1 and the Carp-b-actin splice acceptor sequence of the T2/Onc transposon cassette. cDNA was used as a template in a first round of PCR using specific primers corresponding to exon 1 of Usp9x (59-GAGTCTGCGCTGCCGCTGCTG-39) and Carp-bactin splice acceptor sequence (59-CATACCGGCTACGTTGCTAA-39). The product of this reaction was used as a template in a second round of nested PCR using an internal primer in the Usp9x exon 1 (59-GCTGCCGCTG CTGTTGCTGC-39) and a second primer in the Carp-b-actin splice acceptor sequence (59-ACGTTGCTAACAACCAGTGC-39). PCR products were cloned into pCR 2.1-TOPO vector (Invitrogen) and positives clones sequenced. Plasmids, shRNAs and transfections. pSuperRetro-PURO retroviral vector (Oligoengine) expressed a short hairpin against mouse and human USP9X (59-GATGAGGAACCTGCATTTC-39), mouse Itch (59-GACCTGAGAAGACG TTTGT-39) 31 and a scrambled sequence (59-GCGCGCTTTGTAGGATTCG-39). pBabe-zeo-Ecotropic receptor (ecoR) was obtained from Addgene (plasmid no. 10687). Myc-mItch cDNA was released from pCINeo-Myc-Itch (Addgene plasmid no. 11427), and was subcloned in the retroviral vector pBabe-neo (Addgene plasmid no. 1767). KCU1 and KCU2 cell lines were transfected with pEF-DEST51-mUsp9x(WT)-V5 and pEF-DEST51-mUsp9x(C1566S)-V5 plasmids 32, 33 . The plasmid pEF/GW-51/LacZ (Invitrogen) was used as control. Transfections were done using Lipofectamine 2000 (Invitrogen). Twenty-four hours later, cells were selected with 5 mg ml 21 blasticidin (Invitrogen).
METHODS SUMMARY
anti-Smad4, 1:100 (sc-7966, Santa Cruz). Slides were counterstained with haematoxylin. Clinical patient samples immunohistochemistry and analysis. Tissue microarrays (n 5 404) were prepared from patient samples obtained after appropriate informed consent in Dresden (Institute of Pathology, University Hospital Dresden), Regensburg (Institute of Pathology, University Hospital Regensburg) and Jena (Institute of Pathology, University Hospital Jena). Informed consent was obtained for each patient, following review by the human ethics committee Ethikkommission an der Technischen Universität Dresden. The PDA tumour samples were collected from 1993 to 2009, and most of the patients (65%) did not undergo adjuvant chemotherapy. Those that did undergo adjuvant therapy (35%) were chiefly treated with 5FU or gemcitabine-based regimens, but in this subgroup there was no significant increase in patient survival. The median survival times of patients after surgery from each centre were indistinguishable. Immunohistochemistry was performed on 5 mm sections that were prepared using silanized slides (Menzel Gläser). Staining was performed with the Benchmark System (Ventana), using rabbit anti-USP9X antibody, 1:200 (A301-351A, Bethyl) and anti-ITCH, 1:200 (611198, BD); and the protocol UltraView HRP, with the CC1 modified protocol as pre-treatment. Slides were counterstained with haematoxylin. Staining intensities were scored as absent (0), weak (1), medium (2) and strong (3) . For further analysis the staining intensities were grouped as negative (0) and positive (1) (2) (3) . The Cox regression model assumption of proportional hazard was tested using a plot of the cumulative hazards function.
A second cohort of patient samples was obtained from the Gastrointestinal Cancer Rapid Medical Donation Program in the Department of Pathology at Johns Hopkins Hospital, USA. Use of all human tissue samples from resection specimens and autopsy participants was approved by Johns Hopkins Institutional Review Board, and obtained after informed consent. All samples were collected within 12 h post mortem and formalin fixed before paraffin embedding. Fivemicrometre sections were cut from matched primary and metastasis samples onto glass slides. Slides were first incubated in Dako Target Retrieval Solution for antigen retrieval. Slides were then incubated with rabbit anti-USP9X antibody, 1:1,000 (ab26334, Abcam) or 1:200 (NBP1-48321, Novus Biologicals), and anti-SMAD4 as previously described 38 . Signal detection for immunohistochemistry was accomplished with Dako LSAB1System-HRP. Slides were counterstained with haematoxylin.
An additional cohort of pancreatic cancer resection samples was prospectively acquired through the Australian Pancreatic Cancer Network and the Australian Pancreatic Cancer Genome Initiative (http://www.pancreaticcancer.net.au/apgi). Consent was obtained for genomic sequencing through the Australian Pancreatic Cancer Genome Initiative (APGI) for each individual patient following approval from Human Research Ethics Committees (HREC) at participating sites (Sydney South West Area Health Service HREC Western Zone, 2006/054; Sydney Local Health Network HREC RPA Zone, X11-0220; and North Sydney Central Coast Health, Harbour HREC, 0612-251M). We extracted RNA from tumour samples using the Qiagen Allprep kit (Qiagen) in accordance with the manufacturer's instructions, assayed for quality on an Agilent Bioanalyzer 2100 (Agilent Technologies), and subsequently hybridized to Illumina Human HT-12 V4 microarrays. Raw idat files were processed using IlluminaGeneExpressionIdatReader (M. Cowley et al., manuscript in preparation). After array quality control, these data were vs.t transformed, and then robust spline normalized, using the lumi R/Bioconductor package. For the ICGC/APGI cohort, we assumed a proportional hazard: that the probability of death is the same for those censored as for those remaining on study.
For the TMA and expression array cohorts, median survival was estimated using the Kaplan-Meier method and the difference was tested using the log-rank test. P values of less than 0.05 were considered statistically significant. For the TMA cohort, as few parameters were significant in univariate analysis, all were initially considered for Cox Proportional Hazard multivariate analysis in a backward elimination model, and assessed with the SPSS18 Software (IBM) with overall survival used as the primary endpoint. For the ICGC/APGI cohort, clinicopathological variables analysed with a P value of less than 0.25 on log-rank test were entered into Cox proportional hazard multivariate analysis and the model was resolved using backward elimination. Statistical analysis was performed using StatView 5.0 Software (Abacus Systems). Disease-specific survival was used as the primary endpoint.
